Highest-materiality recent filing
StimCell Energetics engages Stonegate Capital Partners for research coverage; issues 250,000 shares
Stonegate will provide quarterly research, IR consultation, and institutional investor meetings for 12-month term.
Service agreement with St. Boniface Hospital Albrechtsen Research Centre, effective Dec 1, 2025.
Settled $15,000 debt via 75,000 common shares at $0.20 per share.
StimCell Energetics partners with ADM Tronics to redesign eBalance device for home use
Partnership with ADM Tronics (OTCQB: ADMT) to redesign eBalance microcurrent device for home use.
StimCell Energetics engages Think Ink Marketing for six-month investor outreach
Signs marketing services agreement with Think Ink Marketing Data & Email Services, Inc.
Cell MedX completes 1:15 reverse stock split and rebrands as Stimcell Energetics
Reverse split 1:15 effective Nov 1, 2024; shares outstanding reduced from ~297M to ~19.8M.
Cell MedX elects four directors and increases authorized shares to 7.5B
Elected directors: David Jeffs, George Adams, Joao (John) Da Costa, Amir Vahabzadeh effective April 1, 2024.
Cell MedX closes $75k private placement; director and spouse subscribe $30k
Issued 2,500,000 units at $0.03/unit for gross proceeds of $75,000.
Cell MedX director Brad Hargreaves resigns from board, no disagreement cited
Brad Hargreaves resigned from Cell MedX's Board of Directors effective February 27, 2024.
Cell MedX settles $1.62M debt with 231.8M shares at $0.007; new CEO David Jeffs appointed
Dwayne Yaretz resigns as CEO, Brad Hargreaves resigns as VP of Tech & Ops; both remain directors.
Cell MedX Corp. Announces Revocation of British Columbia Cease Trade Order
BCSC revoked cease trade order on Nov 22, 2023, originally issued Oct 11, 2022 for missing filings.
Cell MedX COO resigns, stays as director; audit committee appointed
Joao da Costa resigned as COO on Nov 7, 2023; continues as director.
Cell MedX gets BCSC cease trade order, grants security over eBalance IP on ~$539k loan
BCSC issued cease trade order on Oct 11, 2022 for failing to file annual financial statements due to insufficient audit funds.
Cell MedX appoints Dwayne Yaretz as CEO; former CEO McEnulty remains director
Dwayne Yaretz appointed CEO and to the board on April 25, 2022, replacing Mr. McEnulty as CEO.
On February 27, 2024, Mr. Brad Hargreaves resigned from the Board of Directors of Cell MedX Corp. (the “Company”).
the Company's board of directors was increased to seven (7) directors by the appointment of Mr. Jeffs and Mr. Amir Vahabzadeh as directors
Mr. Brad Hargreaves resigned as Vice President of Technology and Operations of the Company
the Company's board of directors was increased to seven (7) directors by the appointment of Mr. Jeffs and Mr. Amir Vahabzadeh as directors
On December 12, 2023, Mr. Dwayne Yaretz resigned as Chief Executive Officer of the Company
On December 12, 2023, Mr. David Jeffs was appointed as Chief Executive Officer of the Company
On November 7, 2023, Mr. Joao da Costa resigned as Chief Operating Officer of Cell MedX Corp.
who resigned from his position as CEO of the Company on April 25, 2022. Mr. McEnulty will continue to serve on the Company’s board of directors.
to appoint Mr. Dwayne Yaretz as a director to fill the vacancy created by the increase in the number of directors.
Mr. Yaretz was appointed Chief Executive Officer of the Company, replacing Mr. McEnulty, who resigned from his position as CEO.
Max materiality 0.80 · Median 0.43 · Most common event other_material